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Abstract 
Background – Topical therapy is an important alternative to systemic antibacterial therapy for treatment of 
canine superficial pyoderma in light of the emergence of multidrug-resistant staphylococci. Chlorhexidine is 
widely used in shampoo products alone or in combination with miconazole or tromethamine-
ethylenediaminetetraacetic acid (trisEDTA).  Comparisons of these combinations have not been made.   
Hypothesis/Objectives – To determine minimum inhibitory concentrations (MICs) of combinations of 
chlorhexidine/miconazole and chlorhexidine/trisEDTA in vitro in a collection of Staphylococcus 
pseudintermedius (SP) from northern (NUK) and south east (SEUK) United Kingdom (UK). 
Methods – MICs of chlorhexidine, miconazole, trisEDTA and combinations of chlorhexidine/miconazole (1:1) 
or chlorhexidine/trisEDTA (80:16:1 and 80:5:1) were determined for 196 canine SP isolates from NUK (49 
meticillin-resistant [MRSP], 50 meticillin-susceptible [MSSP]) and SEUK (48 MRSP, 49 MSSP) using agar 
dilution.  
Results – TrisEDTA alone did not inhibit growth. Chlorhexidine/miconazole MICs (median = 0.5 mg/L) were 
lower than those of either drug alone (P<0.05) and lower than chlorhexidine/trisEDTA MICs (median = 1 
mg/L; P<0.0005) in each bacterial type and from both regions, except for miconazole in NUK MSSP. An 
additive interaction was noted between chlorhexidine and miconazole or trisEDTA (80:16:1 ratio) in 79 and 
43 isolates, respectively, whereas antagonism between chlorhexidine and trisEDTA was noted for three 
isolates.  NUK isolates were more susceptible than SEUK (P<0.05), except MRSP exposed to chlorhexidine 
and the chlorhexidine/trisEDTA (80:16:1) combination. 
Conclusions and Clinical Importance – These low MICs are likely to be exceeded by topical therapy. 
Evaluation of the mechanisms by which chlorhexidine combinations interact to reduce MICs is warranted, in 
view of increasing concerns of biocide tolerance in staphylococci.  
Introduction 
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In the light of the emergence of multidrug resistant (MDR) staphylococci, especially meticillin-resistant 
Staphylococcus pseudintermedius (MRSP) in veterinary medicine,1 the role of antiseptics is becoming 
increasingly important. Improved treatment strategies for staphylococcal skin disease are needed to limit 
the spread of MRSP and to reduce selective pressure from repeated systemic antimicrobial therapy. Topical 
therapy, in particular with chlorhexidine, has been recommended as an option for treatment of canine 
superficial pyoderma.2 
Previous studies have shown that chlorhexidine shampoo is an effective monotherapy in canine superficial 
pyoderma,3, 4 and in vitro data indicates that chlorhexidine is effective against MRSP as well as its meticillin-
susceptible counterpart (MSSP), and the predominant human commensal (S. aureus; both meticillin-
resistant and susceptible strains).5,6 Genes that encode drug efflux proteins in S. aureus, including qacA/B 
and smr which confer low-level and high-level chlorhexidine resistance respectively,7,8 have rarely been 
described in S. pseudintermedius.9, 10   However, the clinical relevance of this has not been assessed. The 
development of biocide resistance in S. pseudintermedius might well be minimised by combining 
chlorhexidine with other agents with additive or synergistic effects.  Current products used for canine 
superficial skin infections include shampoos containing chlorhexidine alone, or in combination with 
miconazole or tromethamine and ethylenediaminetetraacetic acid (trisEDTA).  Minimum inhibitory 
concentrations (MICs) have been established for miconazole and chlorhexidine in combination, with 
synergistic and additive interactions being shown.5  A shampoo formulation of chlorhexidine and miconazole 
was shown to significantly reduce coagulase-positive staphylococcal counts on seborrhoeic canine skin when 
determined by cup-scrub in a blinded study design.11  In 1987 it was reported that chlorhexidine and 
trisEDTA was more active than chlorhexidine alone against S. aureus;12 although fractional inhibitory 
concentration (FIC) indices were not used to assess the interaction between the drugs. TrisEDTA has been 
shown to enhance the efficacy of marbofloxacin and gentamicin13 against Pseudomonas aeruginosa, and has 
been shown to act synergistically with cefalexin, oxytetracycline, ampicillin, streptomycin and 
sulfadimethoxine against S. aureus.14 This is thought to be due to EDTA damaging the outer cell wall causing 
the bacteria to become more permeable to the antimicrobial agents that act intracellularly.13  
There has been limited investigation into the potential synergistic activity of different ratios of trisEDTA 
amongst chlorhexidine products; furthermore MICs for chlorhexidine / miconazole have not yet been 
compared to chlorhexidine / trisEDTA.  We therefore determined MICs of chlorhexidine, miconazole, trisEDTA 
and the combination of chlorhexidine with either miconazole or trisEDTA in two ratios, in a large collection 
of MRSP and MSSP isolates obtained from the Northern and South-Eastern regions of the United Kingdom. 
Materials and methods 
Bacterial Isolates 
One hundred ninety six S. pseudintermedius isolated from dogs were tested; of these, 49 MRSP and 50 
MSSP were from Northern UK (NUK; the southern border of which were SY, ST, DE, S and YO post codes) 
and 48 MRSP and 49 MSSP from the South East UK (SEUK; from CB, AL, UB and London post codes). All 
NUK isolates were collected from clinical cases obtained in 2011-2015. The SEUK isolates were from a 
collection stored at -80oC in brain-heart infusion broth with 20% glycerol (obtained in 2010-2015); 44 MSSP 
were skin and mucosal carriage isolates and 5 MSSP and 48 MRSP were collected from clinical cases. 
All isolates had been identified to species level through phenotypic methods,  either by a diagnostic 
microbiology laboratory (NUK isolates) or for a previous study (SEUK isolates).15 Briefly, colony morphology 
and haemolytic properties were assessed through growth on blood agar base containing 5% sheep blood; 
coagulase positive staphylococci were identified by clumping factor activity using dog plasma and DNase 
production.16  Phenotypic identification of S. pseudintermedius was confirmed by demonstration of the 
species-specific thermonuclease gene (nuc) by PCR.17  Meticillin resistance was confirmed genotypically by 
demonstrating the presence of mecA by PCR and phenotypically  through growth on mannitol salt agar 
containing 6 mg/L oxacillin.18  
MIC Determination 
MICs were determined by agar dilution according to CLSI guidelines.19 Prior to MIC determination, isolates 
were subcultured twice on blood agar base (CM0271, Oxoid, Basingstoke, UK) containing 5% sheep blood 
(TCS Biosciences, Buckingham, UK) at 35oC for 24 hours. Stock solutions of antimicrobials were prepared 
at 10x final concentration in phosphate-buffered saline (chlorhexidine digluconate C9394, tromethamine 
PHR1347 and ethylenediaminetetraacetic acid (EDTA) EDS; Sigma-Aldrich Inc, Dorset, UK) or 1% DMSO 
(miconazole nitrate PHR1163; Sigma-Aldrich Inc) adjusted for drug potency.19 Serial two-fold dilutions were 
prepared in molten Mueller-Hinton agar, pH 7.2, conforming to (CLSI. Protocols for evaluating dehydrated 
Mueller-Hinton agar; approved standard – second edition. CLSI document M06-A2. Wayne, PA: Clinical and 
Laboratory Standards Institute; 2006) (CM0337, Oxoid). In the first instance an 80:16:1 combination of 
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chlorhexidine digluconate, tromethamine and EDTA was tested, alongside a 1:1 chlorhexidine digluconate 
and miconazole nitrate combination, and each drug alone. Final concentrations of the active fraction ranged 
from 0.125 to 16 mg/L of chlorhexidine digluconate, 0.25 to 64 mg/L of miconazole nitrate, 0.06 to 8 mg/L 
of a 1:1 combination of chlorhexidine digluconate and miconazole nitrate, 0.25 to 512 mg/L of a 16:1 
combination of tromethamine and EDTA, and 0.03 to 16 mg/L of a 80:16:1 combination of chlorhexidine 
digluconate, tromethamine and EDTA.  The study was extended using 185 of the original isolates (NUK MRSP 
n=49, NUK MSSP n=50, SEUK MRSP n=45, SEUK MSSP n=41) to compare an 80:5:1 combination of 
chlorhexidine digluconate, tromethamine and EDTA (0.125 – 16 mg/L), as used in a commercial product, 
with the 1:1 combination of chlorhexidine digluconate and miconazole nitrate (0.125 - 4 mg/L) repeated for 
internal control purposes. Start and end control plates of Mueller-Hinton agar alone were also inoculated in 
each experiment.  Plates were held at 4oC in plastic bags until used within seven days.  
A MIC was recorded as the lowest concentration of antimicrobial agent which completely inhibited colony 
formation, disregarding single colonies or a faint haze of growth.19 Discrepancy between duplicate MICs was 
accepted provided the duplicates varied by only one dilution; in such cases, the higher value was identified 
as the final MIC, as a conservative interpretation.  For quality control purposes three reference strains  (S. 
pseudintermedius LMG 22219 (Belgian Co-ordinated Collections of Micro-organisms, Ghent, Belgium), S. 
aureus American Type Culture Collection (ATCC, Teddington, UK) 25923 and S. aureus ATCC 29663) and 
one MSSA isolate previously reported with high MIC values for miconazole (B122)5 were included.   
Fractional inhibitory concentration (FIC) indices 
The FIC index (FICi) was calculated to analyse drug interaction of chlorhexidine and either miconazole or 
trisEDTA (16:1) when used in combination, using the formula ΣFIC = FICA+FICB = 
(MICAB/MICA)+(MICAB/MICB), where MICA and MICB are the MIC of the drugs when used alone, and MICAB is 
the MIC of the two drugs in combination. FICi were interpreted according to EUCAST guidelines, wherein 
FICi ≤0.5 represented synergy, >0.5 to 1 indicated additivity, >1 to <2 represented indifference, and ≥2 
indicated antagonism.20 
Statistical Analysis 
MICs were compared using a linear mixed effect model (SPSS version 20, IBM United Kingdom Ltd, 
Portsmouth, UK) after log2 transformation, comparing drug, region (NUK and SEUK) and bacterial group 
(MRSP and MSSP) while accounting for repeated measures. Significance was set at P<0.05.   
Results 
TrisEDTA (16:1 ratio) alone did not inhibit growth (MIC ≥ 512 mg/L, n=196) and thus was omitted from 
analysis in the linear mixed effect model. MICs of the 1:1 combination of chlorhexidine and miconazole in 
the initial MIC determination ranged from 0.25 – 2 mg/L (Table 1), with 90.3% (177/196) of isolates having 
an MIC of 0.25 or 0.5 mg/L. Values were very closely similar in the repeat analysis of 185 isolates with a 
range of 0.25 – 1 mg/L and 75% of isolates (139/185) having an MIC of 0.25 or 0.5 mg/L (Table 3).  For 
the whole collection of 196 isolates, chlorhexidine / miconazole MICs (MIC90 = 0.5 mg/L) were significantly 
lower than chlorhexidine alone (P<0.0005; MIC90 chlorhexidine = 2 mg/L), chlorhexidine / trisEDTA 80:16:1 
combination (P<0.0005; MIC90 80:16:1 2 mg/L) and miconazole alone (P<0.005; MIC90 miconazole = 1 
mg/L; except in NUK MSSP). Miconazole MICs were significantly lower than chlorhexidine alone or in 80:16:1 
combination with trisEDTA (P<0.005, Table 1).   
Combination with miconazole reduced the chlorhexidine MICs by zero (n=1), one (n=100), two (n=83) or 
three dilutions (n=12). In 79 of 196 isolates an additive interaction was observed between miconazole and 
chlorhexidine (FICi > 0.5 ≤ 1; Table 2).20 No antagonistic interactions were observed; all other isolates fell 
into the ‘no interaction’ group.  
MICs for chlorhexidine / trisEDTA in 80:16:1 combination (MIC90 2mg/L, range 0.5 – 16 mg/L, Table 1) were 
significantly lower than that of chlorhexidine alone in all bacterial groups (P<0.05) except SEUK MRSP. A 
80:16:1 combination with trisEDTA reduced the chlorhexidine MICs by one dilution in 43 cases, and had no 
effect in 150. There was an additive interaction between chlorhexidine and trisEDTA in a 80:16:1 
combination in 21.9% isolates (43/196) whereas 3 isolates (1.5%) showed an antagonistic interaction where 
the MIC was increased by one dilution (Table 2).  
As with the chlorhexidine / miconazole combination, MICs for the 80:5:1 ratio of chlorhexidine / TrisEDTA 
were closely comparable to those seen with the 80:16:1 ratio; the MIC50 and MIC90 for both combinations 
were 1 and 2 mg/L, respectively, and the lowest MIC was 0.5 mg/L in both studies (Table 3).  As before, 
the chlorhexidine / miconazole combination (MIC50=0.5 mg/L; MIC90= 1.0 mg/L) had greater in vitro activity 
(P<0.0005) than the combination of chlorhexidine and TrisEDTA.   
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Amongst the MSSP, NUK isolates were significantly more susceptible to all drugs (except 80:5:1 
chlorhexidine / trisEDTA) than SEUK isolates (P<0.05; Table 4). In the MRSP groups, SEUK were significantly 
less susceptible to miconazole than NUK isolates (P>0.0005), however no significance was found in 
differences between NUK and SEUK MRSP for the other drugs. 
MRSP had significantly higher MICs of miconazole (NUK MRSP MIC90 = 0.5 mg/L, SEUK MRSP MIC90 = 1 
mg/L) than MSSP (NUK MSSP MIC90 = 0.5 mg/L, SEUK MSSP MIC90 = 0.5 mg/L; P<0.05; Table 4). NUK 
MRSP had significantly higher MICs of chlorhexidine and chlorhexidine / trisEDTA 80:16:1 combination when 
compared with MSSP; however no differences were seen in other MRSP / MSSP comparisons (Table 4). 
Reference strains had MICs equal to or within one dilution of previously established values;5 the quality 
control MSSA isolate (B122) showed more susceptibility to miconazole than previously determined, reflecting 
the overall increased susceptibility to miconazole seen in these results. MICs varied by a single dilution 
between replicates on only six occasions.  
Discussion 
Continued spread of MRSP and the potential for the emergence of tolerance to chlorhexidine8, 9 warrants the 
monitoring of the efficacy of these combination products. Further investigation into the interaction of these 
combinations may indicate whether additive or synergistic combinations can be used to delay development 
of resistance, as well as to improve the efficacy of chlorhexidine. The efficacy of miconazole in this study 
against staphylococci is not unexpected considering previous research documenting its anti-staphylococcal 
activity.21 The good activity of chlorhexidine and miconazole in combination against MRSP and MSSP is in 
accordance with and supports the results of a study of isolates originating from both the UK and Germany.5 
Previously, both synergistic and additive effects have been observed with miconazole and chlorhexidine, 
whereas only additive effects were noted in the present study; these differences appear to reflect a 
somewhat higher activity of miconazole alone.  A degree of variation is well recognised in MIC determinations 
even when standardised protocols are followed.22 Otherwise, MICs of field and reference strains were similar 
to values reported previously and there was good repeatability in the data within this study. The lower MICs 
and increased rates of additivity in this study indicated that the combination of miconazole / chlorhexidine 
is more efficacious in vitro than both tested combinations of trisEDTA /chlorhexidine.  
The combination of trisEDTA with chlorhexidine resulted in lower MICs than with chlorhexidine alone (in 
most cases), however this appears modest in comparison to the enhancement seen when trisEDTA is 
combined with marbofloxacin or gentamicin against Pseudomonas aeruginosa.13 This may reflect a difference 
between the effect of TrisEDTA on Gram-positive and negative bacteria, or could indicate that the mechanism 
of activity of chlorhexidine is not improved by the increased permeability afforded to the bacteria by the 
action of TrisEDTA. The mechanisms of interaction of these combinations warrants further investigation. The 
emergence of MRSP is attributed to the expansion of a few dominant lineages, rather than the acquisition of 
resistance genes by multiple lineages;1 this is similar to the clonal expansion of MRSA in human medicine. 
This may account for the lack of regional differences in MIC amongst this study’s MRSP isolates. More 
regional variability in MSSP MICS likely reflects greater genetic diversity in this group,9 but the overall low 
MICs for both NUK and SEUK regions indicates that there should be no difference in response to treatment 
with these combinations according to region.  
The low MICs in this study showed that chlorhexidine shampoos are rational choices for treatment of canine 
superficial pyoderma associated with S. pseudintermedius, including MRSP. The combination of chlorhexidine 
with miconazole showed apparent superiority over combination with trisEDTA in vitro, though product 
formulation, ability of the antiseptic to penetrate into the infected area of skin and client compliance may 
have confounding effects on treatment that must be investigated through in vivo studies. The very limited 
differences in susceptibility  amongst MSSP and the apparent absence of regional differences amongst MRSP 
indicates that topical therapy remains an important option for veterinarians in the treatment of canine 
superficial pyoderma. 
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Table 1: MICs of chlorhexidine (alone), miconazole (alone), chlorhexidine and miconazole in a 1:1 combination and chlorhexidine, tromethamine and EDTA 
in an 80:16:1 ratio for 196 Staphylococcus pseudintermedius isolates from dogs1  
Drug Bacterial Type 
MIC / mg/L 
2MIC50 MIC90 
0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 
Chlorhexi
dine 
NUK MRSP Not tested Not tested 0 0 0 16 25 8 0 0 Not tested Not tested 2 4 
NUK MSSP Not tested Not tested 0 0 0 36 14 0 0 0 Not tested Not tested 1 2 
SEUK MRSP Not tested Not tested 0 0 0 21 24 2 1 0 Not tested Not tested 2 2 
SEUK MSSP Not tested Not tested 0 0 1 25 18 2 3 0 Not tested Not tested 1 4 
Total Not tested Not tested 0 0 1 98 81 12 4 0 Not tested Not tested 1 2 
Miconazol
e 
NUK MRSP Not tested Not tested Not tested 
0 37 12 0 0 0 0 0 0 
0.5 1 
NUK MSSP Not tested Not tested Not tested 
2 48 0 0 0 0 0 0 0 
0.5 0.5 
SEUK MRSP Not tested Not tested Not tested 
0 1 44 2 1 0 0 0 0 
1 1 
SEUK MSSP Not tested Not tested Not tested 
0 33 8 4 4 0 0 0 0 
0.5 2 
Total Not tested Not tested Not tested 
2 119 64 6 5 0 0 0 0 
0.5 1 
1:1 
Chlorhexi
dine / 
miconazo
le 
NUK MRSP Not tested 0 0 
2 47 0 0 0 0 Not tested Not tested Not tested 
0.5 0.5 
NUK MSSP Not tested 0 0 
8 42 0 0 0 0 Not tested Not tested Not tested 
0.5 0.5 
SEUK MRSP Not tested 0 0 
0 41 6 1 0 0 Not tested Not tested Not tested 
0.5 1 
SEUK MSSP Not tested 0 0 
4 33 9 3 0 0 Not tested Not tested Not tested 
0.5 1 
Total Not tested 0 0 
14 163 15 4 0 0 Not tested Not tested Not tested 
0.5 0.5 
80:16:1 
chlorhexi
dine / 
trometha
mine / 
EDTA  
NUK MRSP 0 0 0 
0 0 23 20 6 0 0 Not tested Not tested 
2 4 
NUK MSSP 0 0 0 
0 1 47 2 0 0 0 Not tested Not tested 
1 1 
SEUK MRSP 0 0 0 
0 0 25 20 2 1 0 Not tested Not tested 
1 2 
SEUK MSSP 0 0 0 
0 1 42 1 2 0 3 Not tested Not tested 
1 4 
Total 0 0 0 
0 2 137 43 10 1 3 Not tested Not tested 
1 2 
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MRSP, meticillin-resistant S. pseudintermedius; MSSP, meticillin-susceptible S. pseudintermedius; NUK, isolates of Northern UK origin; SEUK, isolates of 
a South-Eastern UK origin.  
NUK MRSP n=49, NUK MSSP n=50, SEUK MRSP n=48, SEUK MSSP n=49.  
1MICs for trisEDTA (alone) are not included as MIC >512 mg/L was established for all 196 isolates. 
2MIC50 is equal to the median value. 
 
Table 2: Interpretation of fractional inhibitory concentration indices for a 1:1 combination of chlorhexidine and miconazole and an 80:16:1 combination of 
chlorhexidine, tromethamine and EDTA (trisEDTA) for 196 Staphylococcus pseudintermedius isolates from dogs 
 
Drug Combination Bacterial Group 
Synergy 
≤0.5 
Additive 
>0.5-≤1 
Indifference 
>1-≤2 
Antagonism 
>2 
1:1 chlorhexidine and 
miconazole 
N MRSP (n=49) 0 14 35 0 
N MSSP (n=50) 0 6 44 0 
SE MRSP (n=48) 0 43 5 0 
SE MSSP (n=49) 0 16 33 0 
Total 0 79 117 0 
80:16:1 combination of 
chlorhexidine, 
tromethamine and EDTA 
(trisEDTA) 
N MRSP (n=50) 0 9 40 0 
N MSSP (n=50) 0 13 37 0 
SE MRSP (n=49) 0 4 44 0 
SE MSSP (n=49) 0 17 29 3 
Total 0 43 150 3 
 
MRSP, meticillin-resistant S. pseudintermedius; MSSP, meticillin-susceptible S. pseudintermedius; N, isolates of Northern UK origin; SE, isolates of a 
South-Eastern UK origin   
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Table 3: MICs of chlorhexidine and miconazole in a 1:1 combination and chlorhexidine, tromethamine and EDTA in an 80:5:1 ratio for 185 Staphylococcus 
pseudintermedius isolates from dogs1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MRSP, meticillin-resistant S. pseudintermedius; MSSP, meticillin-susceptible S. pseudintermedius; NUK, isolates of Northern UK origin; SEUK, isolates of 
a South-Eastern UK origin.  
NUK MRSP n=49, NUK MSSP n=50, SEUK MRSP n=45, SEUK MSSP n=41.  
1MIC50 is equal to the median value. 
 
  
Drug Bacterial Type 
MIC / mg/L 
1MIC50 MIC90 
0.125 0.25 0.5 1 2 4 8 16 
1:1 
Chlorhexidine / 
miconazole 
NUK MRSP 0 
0 43 6 0 0 Not tested 
Not 
tested 0.5 1 
NUK MSSP 0 
1 49 0 0 0 Not tested 
Not 
tested 0.5 0.5 
SEUK MRSP 0 
0 16 29 0 0 Not tested 
Not 
tested 1 1 
SEUK MSSP 0 
0 30 11 0 0 Not tested 
Not 
tested 0.5 1 
Total 0 
1 138 46 0 0 Not tested 
Not 
tested 0.5 1 
80:5:1 
chlorhexidine / 
tromethamine / 
EDTA  
NUK MRSP 0 
0 0 18 20 1 0 0 
2 4 
NUK MSSP 0 
0 0 35 14 1 0 0 
1 2 
SEUK MRSP 0 
0 0 21 22 2 0 0 
2 2 
SEUK MSSP 0 
0 1 23 15 2 0 0 
1 2 
Total 0 
0 1 97 71 16 0 0 
1 2 
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Table 4: Comparisons (P values) of MIC of chlorhexidine, miconazole and combinations of chlorhexidine with either miconazole or tromethamine and EDTA 
amongst Staphylococcus pseudintermedius isolates grouped by UK region (NUK and SEUK) and bacteria type (MRSP and MSSP)1 
 Chlorhexidine2 Miconazole2 
1:1 Chlorhexidine / 
miconazole2 
80:16:1 Chlorhexidine / 
tromethamine / EDTA2 
80:5:1 Chlorhexidine / 
tromethamine / EDTA3 
NUK versus SEUK 
MRSP 
0.128 <0.0005 0.098 0.470 
0.254 
NUK versus SEUK 
MSSP 
0.008 <0.0005 0.002 0.014 
0.118 
MRSP versus 
MSSP NUK 
<0.0005 0.022 0.337 <0.0005 
0.496 
MRSP versus 
MSSP SEUK 
0.789 <0.0005 0.644 0.060 
0.124 
 
1P value < 0.05 is considered significant. Significant values are in bold. 2n = 196 S. pseudintermedius isolates 3n = 185 S. pseudintermedius isolates    
